<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952313</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-CP-301</org_study_id>
    <nct_id>NCT02952313</nct_id>
  </id_info>
  <brief_title>Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study</brief_title>
  <official_title>Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirox, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirox, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to obtain outcomes data in subjects with severe to extreme
      class NOSE scores undergoing placement of the Spirox Latera Implant with or without
      concurrent septoplasty and/or turbinate reduction procedures in an operating room setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Efficacy Endpoint is the Percent of Treatment Responders</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Nasal Procedure and Latera™ Device-related Adverse Events</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Number of participants with a device-related or procedure-related adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Treatment Responders</measure>
    <time_frame>1, 3 12, 18 and 24 months post procedure.</time_frame>
    <description>Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasal Airway Obstruction From Baseline Using the Visual Analog Scale (VAS).</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months post procedure</time_frame>
    <description>Change from baseline in VAS score for ability to breathe through the nose. Participants provide scores on a scale of 0 (easy to breathe through the nose) to 100 (unable to breathe through the nose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure and Device Related Adverse Events</measure>
    <time_frame>12, 18 and 24 months post procedure</time_frame>
    <description>Number of participants who experience procedure or device-related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Nasal Obstruction</condition>
  <arm_group>
    <arm_group_label>Latera Implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants have unilateral or bilateral placement of LATERA Nasal Implants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal Implant</intervention_name>
    <arm_group_label>Latera Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has Nasal Obstruction Symptom Evaluation (NOSE) Score ≥55.

          2. The subject has dynamic lateral nasal wall insufficiency as confirmed by Positive
             Modified Cottle Maneuver22.

          3. The subject is ≥18 years of age.

          4. The subject is willing and able to provide informed consent and comply with the study
             protocol.

          5. The subject is seeking treatment for nasal airway obstruction due to Nasal Valve
             Collapse (NVC) and is willing to undergo nasal Implant procedure alone or with
             septoplasty and/or a turbinate reduction procedure in an operating room setting.

          6. The subject has appropriate nasal and facial anatomy to receive Latera Implant.

          7. The subject agrees to follow-up examinations through twelve (12) months post
             operatively.

          8. The subject has failed a trial of appropriate maximal medical management [e.g., nasal
             steroids (at least 4 weeks); antihistamines; oral decongestants; nasal strips, stents,
             or cones]. Failure of maximal medical management may be from lack of effectiveness or
             inability of subject to tolerate.

        Exclusion Criteria:

          1. The subject is having a concurrent Functional Endoscopic Sinus Surgery (FESS) or
             sinuplasty.

          2. The subject has had rhinoplasty within the past twelve (12) months.

          3. The subject is planning to have other concurrent rhinoplasty procedure.

          4. The subject is planning to have other rhinoplasty procedures or will use external
             dilators within twelve (12) months after the index procedure.

          5. The subject has had septoplasty and/or inferior turbinate reduction within the past
             six (6) months.

          6. The subject has, in the view of the clinician, inappropriate fixation on their nasal
             airway.

          7. The subject plans to have any surgical or non-surgical treatment of their nasal valve,
             other than the index procedure, within twelve (12) months of the study.

          8. The subject has a permanent Implant or dilator in the nasal area.

          9. The subject has concomitant inflammatory or infectious skin conditions or unhealed
             wounds in the treatment area.

         10. The subject currently has active nasal vestibulitis.

         11. The subject has a history of nasal vasculitis.

         12. The subject is a chronic systemic steroid or recreational intra-nasal drug user.

         13. The subject has had a cancerous or pre-cancerous lesion and/or has had radiation
             exposure in the treatment area or chemotherapy.

         14. The subject has polyps or pathology other than septal deviation and/or turbinate
             hypertrophy and/or lateral wall insufficiency that would contribute to airway
             obstruction.

         15. The subject has a history of a significant bleeding disorder(s) that would prevent
             healing of the treatment area post procedure.

         16. The subject has a known or suspected allergy to poly lactic acid (PLA) or other
             absorbable materials.

         17. The subject has a significant systemic disease such as poorly controlled diabetes
             which, in the investigator's opinion, could pre-dispose the subject to poor wound
             healing.

         18. The subject is currently using nasal oxygen or continuous positive airway pressure
             (CPAP).

         19. The subject is not a candidate for procedures conducted under general anesthesia,
             managed anesthesia care (MAC) or conscious sedation.

         20. If female, subject is known or suspected to be pregnant or is lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beverly Hills Aesthetic Surgical Institute</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT Assoc. of South Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sinus, Allergy &amp; Sleep Wellness</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Nasal &amp; Sinus Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT New Orelans</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison ENT &amp; Facial Plastic Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont ENT</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT &amp; Allergy Center of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collin County ENT</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogden Clinic</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <results_first_submitted>March 7, 2019</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02952313/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02952313/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Latera Implant</title>
          <description>All participants have unilateral or bilateral placement of LATERA Nasal Implants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Latera Implant</title>
          <description>All participants have unilateral or bilateral placement of LATERA Nasal Implants.
Nasal Implant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Non-Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unspecified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NOSE Score (100-point scale)</title>
          <description>Nasal Obstruction Symptom Evaluation (NOSE) scale quantifies symptom severity of nasal obstruction. The tool is comprised of 5 questions (nasal congestion, nasal obstruction, trouble nose breathing, trouble sleeping, and difficulty breathing during exercise or exertion) that are rated from 0 (no problem) to 4 (severe problem). The scores for each item are summed, multiplied by 5, and reported on a 100-point scale. Scores of 5 to 25 indicate mild, 30-50 moderate, 55-75 severe, and 80-100 extreme symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.5" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NOSE Severity Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Severe (NOSE Scores of 55-75)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme (Nose Scores of 80-100</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Efficacy Endpoint is the Percent of Treatment Responders</title>
        <description>Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).</description>
        <time_frame>6 months post procedure</time_frame>
        <population>All participants with 6-month NOSE scores</population>
        <group_list>
          <group group_id="O1">
            <title>Latera Implant</title>
            <description>All participants have unilateral or bilateral placement of LATERA Nasal Implants.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Efficacy Endpoint is the Percent of Treatment Responders</title>
          <description>Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).</description>
          <population>All participants with 6-month NOSE scores</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint: Nasal Procedure and Latera™ Device-related Adverse Events</title>
        <description>Number of participants with a device-related or procedure-related adverse event</description>
        <time_frame>6 months post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latera Implant</title>
            <description>All participants with unilateral or bilateral placement of LATERA Nasal Implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint: Nasal Procedure and Latera™ Device-related Adverse Events</title>
          <description>Number of participants with a device-related or procedure-related adverse event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Treatment Responders</title>
        <description>Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).</description>
        <time_frame>1, 3 12, 18 and 24 months post procedure.</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nasal Airway Obstruction From Baseline Using the Visual Analog Scale (VAS).</title>
        <description>Change from baseline in VAS score for ability to breathe through the nose. Participants provide scores on a scale of 0 (easy to breathe through the nose) to 100 (unable to breathe through the nose).</description>
        <time_frame>1, 3, 6, 12, 18 and 24 months post procedure</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction Questionnaire</title>
        <description>Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.</description>
        <time_frame>6 months</time_frame>
        <population>All participants with satisfaction questionnaires completed at the 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Latera Implant</title>
            <description>All participants have unilateral or bilateral placement of LATERA Nasal Implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction Questionnaire</title>
          <description>Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.</description>
          <population>All participants with satisfaction questionnaires completed at the 6-month follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure and Device Related Adverse Events</title>
        <description>Number of participants who experience procedure or device-related adverse events.</description>
        <time_frame>12, 18 and 24 months post procedure</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events for the primary safety endpoint are reported for the 6-month period after the study procedure.</time_frame>
      <desc>Adverse events were systematically collected completion of standardized case report forms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Latera Implant</title>
          <description>All participants with unilateral or bilateral placement of LATERA Nasal Implants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <description>Patient experienced a GI bleed 3 months after the implant procedure. Unrelated to implant or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implant retrieval/extrusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Additional publications are restricted to after publication of the multicenter study results. The only other restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Clinical Research &amp; Publications Manager</name_or_title>
      <organization>Stryker ENT</organization>
      <phone>763-463-1598</phone>
      <email>ellen.omalley@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

